InnovAtlasMalaria No More
Pharmaceutical and biotech company

HDT Bio

Develop

HDT Bio develops RNA vaccine technologies and provides its repRNA/LION™ platform for next-generation malaria vaccines being developed with MalarVx.

0
Endemic countries
1
U.S. states
1
Products and programs
About

What they do

HDT Bio develops RNA vaccine technologies and provides its repRNA/LION™ platform for next-generation malaria vaccines being developed with MalarVx.1,2 The platform combines self-amplifying replicon RNA with HDT Bio’s LION™ nanocarrier to improve vaccine delivery, immune responses, stability, and manufacturing.3,4,2 Under a 2025 license agreement, HDT Bio is also providing development and commercialization support for MalarVx’s malaria vaccine program.2 Its U.S. R&D is based in Seattle and Redmond, Washington, and the malaria work is at the development stage2,5

In the United States
Products and programs

In the field and in development

RepRNA/LION™ self-amplifying RNA and lipid-nanoparticle platform licensed to MalarVx for malaria vaccines2
Where they work

Partnerships

No endemic-country partnerships are listed.

U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1hdt.bio
  2. 2Confirmed by the organization
  3. 3malarvx.com
  4. 4hdt.bio
  5. 5hdt.bio